Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2018 (2018), Article ID 4256365, 5 pages
https://doi.org/10.1155/2018/4256365
Case Report

GNQ-209P Mutation in Metastatic Uveal Melanoma and Treatment Outcome

1Department of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, USA
2Department of Interventional Radiology, University of Cincinnati, Cincinnati, OH, USA
3Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA

Correspondence should be addressed to Ihab Eldessouki; moc.oohay@led_bahi

Received 28 November 2017; Accepted 11 March 2018; Published 4 April 2018

Academic Editor: Raffaele Palmirotta

Copyright © 2018 Nagla Abdel Karim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Singh, L. Bergman, and S. Seregard, “Uveal melanoma: epidemiologic aspects,” Ophthalmology Clinics of North America, vol. 18, no. 1, pp. 75–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Scotto, J. F. Fraumeni, and J. A. Lee, “Melanomas of the eye and other noncutaneous sites: epidemiologic aspects,” Journal of the National Cancer Institute, vol. 56, no. 3, pp. 489–491, 1976. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Kujala, T. Ma¨kitie, and T. Kivela¨, “Very long-term prognosis of patients with malignant uveal melanoma,” Investigative Opthalmology and Visual Science, vol. 44, no. 11, p. 4651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Diener-West, S. M. Reynolds, D. J. Agugliaro et al., “Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: collaborative ocular melanoma study group report no. 26,” Archives of Ophthalmology, vol. 123, no. 12, pp. 1639–1643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. The Collaborative Ocular Melanoma Study Group, “Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15,” Archives of Ophthalmology, vol. 119, no. 5, pp. 670–676, 2001. View at Publisher · View at Google Scholar
  6. S. Bakalian, J. C. Marshall, P. Logan et al., “Molecular pathways mediating liver metastasis in patients with uveal melanoma,” Clinical Cancer Research, vol. 14, no. 4, pp. 951–956, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. D. Van Raamsdonk, K. G. Griewank, M. B. Crosby et al., “Mutations in GNA11 in uveal melanoma,” New England Journal of Medicine, vol. 363, no. 23, pp. 2191–2199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. Neves, P. T. Ram, and R. Iyengar, “G protein pathways,” Science, vol. 296, no. 5573, pp. 1636–1639, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Markby, R. Onrust, and H. Bourne, “Separate GTP binding and GTPase activating domains of a G alpha subunit,” Science, vol. 262, no. 5141, pp. 1895–1901, 1993. View at Publisher · View at Google Scholar
  10. C. D. Van Raamsdonk, V. Bezrookove, G. Green et al., “Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi,” Nature, vol. 457, no. 7229, pp. 599–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Lamba, L. Felicioni, F. Buttitta et al., “Mutational profile of GNAQQ209 in human tumors,” PLoS One, vol. 4, no. 8, 2009, article e6833. View at Publisher · View at Google Scholar · View at Scopus
  12. M. D. Onken, L. A. Worley, M. D. Long et al., “Oncogenic mutations in GNAQ occur early in uveal melanoma,” Investigative Opthalmology and Visual Science, vol. 49, no. 12, pp. 5230–5234, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Bauer, E. Kilic, J. Vaarwater, B. C. Bastian, C. Garbe, and A. De Klein, “Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma,” British Journal of Cancer, vol. 101, no. 5, pp. 813–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Landis, S. B. Masters, A. Spada, A. M. Pace, H. R. Bourne, and L. Vallar, “GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours,” Nature, vol. 340, no. 6236, pp. 692–696, 1989. View at Publisher · View at Google Scholar
  15. G. Kalinec, A. J. Nazarali, S. Hermouet, N. Xu, and J. S. Gutkind, “Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells,” Molecular and Cellular Biology, vol. 12, no. 10, pp. 4687–4693, 1992. View at Publisher · View at Google Scholar
  16. J. Sondek, D. G. Lambright, J. P. Noel, H. E. Hamm, and P. B. Sigler, “GTPase mechanism of Gproteins from the 1.7-Å crystal structure of transducin α - GDP AIF−4,” Nature, vol. 372, no. 6503, pp. 276–279, 1994. View at Publisher · View at Google Scholar
  17. P. B. Schiff and S. B. Horwitz, “Taxol stabilizes microtubules in mouse fibroblast cells,” Proceedings of the National Academy of Sciences, vol. 77, no. 3, pp. 1561–1565, 1980. View at Publisher · View at Google Scholar
  18. R. A. Leon-Ferre and S. N. Markovic, “Nab-paclitaxel in patients with metastatic melanoma,” Expert Review of Anticancer Therapy, vol. 15, no. 12, pp. 1371–1377, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. J. J. Luke, P. L. Triozzi, K. C. McKenna et al., “Biology of advanced uveal melanoma and next steps for clinical therapeutics,” Pigment Cell and Melanoma Research, vol. 28, no. 2, pp. 135–147, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. S. S. Agarwala, A. M. M. Eggermont, S. O’Day, and J. S. Zager, “Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options,” Cancer, vol. 120, no. 6, pp. 781–789, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. N. A. Karim, J. Schuster, I. Eldessouki et al., “Pulmonary sarcomatoid carcinoma: University of Cincinnati experience,” Oncotarget, vol. 9, no. 3, 2018. View at Publisher · View at Google Scholar
  22. N. Karim, I. Eldessouki, M. Yellu, T. Namad, J. Wang, and O. Gaber, “A case study in advanced lung cancer patients with vimentin over expression,” Clinical Laboratory, vol. 63, no. 10, 2017. View at Publisher · View at Google Scholar
  23. J. F. Pingpank, M. S. Hughes, H. R. Alexander et al., “A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma,” Journal of Clinical Oncology, vol. 28, no. 18, p. LBA8512, 2010. View at Publisher · View at Google Scholar
  24. J. C. Moser, J. S. Pulido, R. S. Dronca, R. R. McWilliams, S. N. Markovic, and A. S. Mansfield, “The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma,” Melanoma Research, vol. 25, no. 1, pp. 59–63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. L. E. Flaherty, J. M. Unger, P. Y. Liu, W. C. Mertens, and V. K. Sondak, “Metastatic melanoma from intraocular primary tumors,” American Journal of Clinical Oncology, vol. 21, no. 6, pp. 568–572, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Kivelä, S. Suciu, J. Hansson et al., “Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma,” European Journal of Cancer, vol. 39, no. 8, pp. 1115–1120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. T. J. Smith, S. Temin, E. R. Alesi et al., “American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care,” Journal of Clinical Oncology, vol. 30, no. 8, pp. 880–887, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. E. M. Hersh, M. Del Vecchio, M. P. Brown, and R. F. Kefford, “Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM),” Pigment Cell & Melanoma Research, vol. 25, p. 863, 2012. View at Google Scholar
  29. P. J. Hesketh, M. G. Kris, E. Basch et al., “Antiemetics: American Society of Clinical Oncology clinical practice guideline update,” Journal of Clinical Oncology, vol. 35, no. 28, pp. 3240–3261, 2017. View at Publisher · View at Google Scholar · View at Scopus